免疫組織化学(IHC)市場

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2021年11月

免疫組織化学(IHC)市場:製品(抗体、試薬、機器、キット)、用途[診断(がん、感染症、自己免疫疾患)、研究、法医学]、エンドユーザー(病院、臨床検査室、アカデミア)別 – 2026年までの世界予測

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End user (Hospitals, Diangostic labs, Academia) – Global Forecast to 2026

ページ数 339
図表数 390
種別 英文調査報告書

目次  お問合せ

The global immunohistochemistry market is projected to reach USD 3.3 billion by 2026 from USD 2.3 billion in 2021, at a CAGR of 7.7% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases, technological advancements in IHC, and availability of reimbursements for IHC tests. However, the high degree of consolidation in the by the major market players is expected to restrain the growth of this market during the forecast period.

“The Kits product segment accounted for the highest growth rate in the immunohistochemistry market, by product, during the forecast period”
In 2020, the Kits product segment accounted for the share of around 12% of the immunohistochemsitry market. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls among diagnostic laboratories, hospitals, research institutes, and other end users, is growing. Moreover, ready-to-use kits simplify the IHC process by rectifying the initial time-consuming selections of primary antibodies and appropriate stains. This is fueling the growth of the immunohistochemistry kits market.

“Diagnostic applications segment accounted for the largest share of the application segment”
Based on application, the IHC market is segmented into diagnostic, research, and forensic applications. The Diagnostic application segment dominated this market in 2020 and is estimated to register the highest growth during the forecast period. The growth of this segment is majorly attributed to factors such as the advantages of IHC over traditionally used special enzyme staining techniques that identify only a limited number of proteins, enzymes, and tissue structures. Therefore, IHC has become a crucial technique and is widely used for medical research as well as clinical diagnostics.

“Hospitals & Diagnostic Laboratories segment accounted for the largest share of the end user segment”
Based on end user, the IHC market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share (74.8%) of the IHC market in 2020. The increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures in hospitals, and the increasing trend of establishing in-house diagnostic capabilities in hospitals to provide time-bound and affordable patient services are factors driving the growth of this market segment.
“Asia Pacific: The fastest-growing region in the immunohistochemistry market”
Based on the region, the immunohistochemistry market is broadly segmented into North America, Europe, Asia-Pacific and Rest of the World. APAC is expected to register the fastest growth rate during the forecast period owing to several factors, including increasing disposable income, rising healthcare spending, growing demand for quality medical care, and increasing investments by pharmaceutical and biopharmaceutical companies. The rising prevalence of chronic ailments, rapidly increasing geriatric population, growing academic and government investments in diagnostic research, and the presence of many market players are the other major factors driving the growth of the immunohistochemistry market in APAC.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: Managers – 55%, CXOs – 20%, and Executives – 25%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• F. Hoffman-La Roche AG (Switzerland)
• Danaher Corporation (US)
• Agilent Technologies, Inc. (US)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (US)
• Bio-Techne Corporation (US)
• Abcam plc (UK)
• Becton, Dickinson and Company (US)
• PerkinElmer, Inc. (US)
• Takara Bio, Inc. (Japan)
• Thermo Fisher Scientific, Inc. (US)
• PHC Holdings Corporation (Japan)
• Cell Signaling Technology, Inc. (US)
• Bio SB, Inc. (US)
• Miltenyi Biotec (Germany)
• CANDOR Bioscience GmbH (Germany)
• Sakura Finetek Japan Co., Ltd. (Japan)
• Eagle Biosciences, Inc. (US)
• Biocare Medical, LLC (US)
• Elabscience, Inc. (China)
• Biogenex Laboratories (US)
• Diagnostic Biosystems, Inc. (US)
• BioVision Inc. (US)
• Rockland Immunochemicals, Inc. (US)
• Genemed Biotechnologies, Inc. (US)
Research Coverage:
This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemsitry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, challenges and opportunities.


目次

1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 45
1.2.1 INCLUSIONS & EXCLUSIONS 45
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS 45
1.3 MARKET SCOPE 46
1.3.1 MARKETS COVERED 46
1.3.2 YEARS CONSIDERED FOR THE STUDY 47
1.4 CURRENCY 47
1.5 LIMITATIONS 47
1.6 STAKEHOLDERS 48
1.7 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
FIGURE 1 RESEARCH DESIGN 50
2.1.1 SECONDARY DATA 51
2.1.2 PRIMARY DATA 52
FIGURE 2 BREAKDOWN OF PRIMARIES: IHC MARKET 52
2.2 MARKET ESTIMATION METHODOLOGY 53
FIGURE 3 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) 2020 53
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020 53
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 55
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 55
2.3 MARKET GROWTH RATE PROJECTIONS 56
FIGURE 6 IHC MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 56
FIGURE 7 IHC MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 57
2.4 DATA TRIANGULATION 58
FIGURE 8 DATA TRIANGULATION METHODOLOGY 58
2.5 RESEARCH ASSUMPTIONS 59
2.5.1 COVID-19 SPECIFIC ASSUMPTIONS 59
2.6 RISK ANALYSIS 60
3 EXECUTIVE SUMMARY 61
FIGURE 9 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 61
FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2020 62
FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021−2026 62
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF IMMUNOHISTOCHEMISTRY MARKET 63
4 PREMIUM INSIGHTS 64
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 64
FIGURE 13 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 64
4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2020) 65
FIGURE 14 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2020 65
4.3 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE 65
FIGURE 15 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 16 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
TABLE 2 IHC MARKET: IMPACT ANALYSIS 67
5.2.1 DRIVERS 67
5.2.1.1 Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases 67
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050) 68
FIGURE 17 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020 69
5.2.1.2 Technological advancements in IHC 69
5.2.1.3 Availability of reimbursements for IHC tests 69
TABLE 4 CPT CODES FOR IHC PROCEDURES 70
5.2.2 RESTRAINTS 70
5.2.2.1 High degree of consolidation 70
TABLE 5 MAJOR ACQUISITIONS IN THE MARKET, 2018–2021 71
5.2.3 OPPORTUNITIES 71
5.2.3.1 Increasing demand for personalized medicine 71
5.2.3.2 Growing significance of companion diagnostics 71
5.2.3.3 Growth opportunities in emerging countries 72
5.2.4 CHALLENGES 72
5.2.4.1 Dearth of skilled professionals 72
TABLE 6 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 73
5.2.4.2 Product failures and recalls 73
5.3 RANGES/SCENARIO 74
FIGURE 18 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF IHC MARKET 74
5.4 IMPACT OF COVID-19 OUTBREAK ON IHC MARKET 74
FIGURE 19 IHC MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021 75
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
FIGURE 20 REVENUE SHIFT & NEW POCKET FOR IHC PROVIDERS 77
5.6 PRICING ANALYSIS 77
TABLE 7 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2020) 77
5.7 VALUE CHAIN ANALYSIS 78
FIGURE 21 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE 78
5.8 ECOSYSTEM ANALYSIS 79
FIGURE 22 ECOSYSTEM ANALYSIS: IHC MARKET 79
TABLE 8 SUPPLY CHAIN ECOSYSTEM 80
5.9 TECHNOLOGY ANALYSIS 81
5.10 PATENT ANALYSIS 82
FIGURE 23 PATENT GRANTED FOR IHC IN LAST 10 YEARS 82
TABLE 9 INDICATIVE LIST OF PATENTS IN IHC MARKET 83
5.11 REGULATORY ANALYSIS 84
5.11.1 US 84
TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 84
FIGURE 24 US: REGULATORY PROCESS FOR IVD DEVICES 85
5.11.2 CANADA 86
FIGURE 25 CANADA: REGULATORY PROCESS FOR IVD DEVICES 86
5.11.3 EUROPE 86
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 86
FIGURE 26 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 87
5.11.4 JAPAN 88
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 88
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS 88
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.11.5 CHINA 89
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.11.6 INDIA 90
FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES 90
5.11.7 BRAZIL 91
FIGURE 29 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 91
5.12 PORTER’S FIVE FORCES ANALYSIS 92
TABLE 15 IHC MARKET: PORTER’S FIVE FORCES ANALYSIS 92
5.12.1 THREAT OF NEW ENTRANTS 92
5.12.2 THREAT OF SUBSTITUTES 92
5.12.3 BARGAINING POWER OF BUYERS 93
5.12.4 BARGAINING POWER OF SUPPLIERS 93
5.12.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 93

6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
TABLE 16 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 95
6.2 ANTIBODIES 95
TABLE 17 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION,
2019–2026 (USD MILLION) 96
TABLE 18 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY COUNTRY, 2019–2026 (USD MILLION) 96
TABLE 19 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY COUNTRY, 2019–2026 (USD MILLION) 96
TABLE 20 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 21 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION) 97
TABLE 22 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 97
6.2.1 PRIMARY ANTIBODIES 98
6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies 98
TABLE 23 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION) 98
TABLE 24 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION) 98
TABLE 25 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 26 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 27 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY REGION, 2019–2026 (USD MILLION) 99
6.2.2 SECONDARY ANTIBODIES 100
6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to drive market for secondary antibodies 100
TABLE 28 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY REGION, 2019–2026 (USD MILLION) 100
TABLE 29 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 30 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 31 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 32 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY REGION, 2019–2026 (USD MILLION) 102
6.3 REAGENTS 102
TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 36 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 37 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2019–2026 (USD MILLION) 104
TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 104
6.3.1 HISTOLOGICAL STAINS 104
6.3.1.1 Developments in concurrent detection of multiple antigenic sites within single tissue specimen and cancer disease progression studies to propel market growth 104
TABLE 39 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2019–2026 (USD MILLION) 105
TABLE 40 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 41 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS,
BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 42 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS,
BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 43 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS,
BY REGION, 2019–2026 (USD MILLION) 106
6.3.2 BLOCKING SERA AND REAGENTS 107
6.3.2.1 Blocking sera and reagents prevent nonspecific binding and reduce background noise and potentially false-positive results 107
TABLE 44 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION) 107
TABLE 45 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 46 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 47 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 48 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION) 108
6.3.3 CHROMOGENIC SUBSTRATES 109
6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period 109
TABLE 49 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES,
BY REGION, 2019–2026 (USD MILLION) 109
TABLE 50 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 51 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 52 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 53 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2019–2026 (USD MILLION) 110

6.3.4 FIXATION REAGENTS 111
6.3.4.1 North America is largest market for fixation reagents 111
TABLE 54 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2019–2026 (USD MILLION) 111
TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 111
TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 57 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 112
TABLE 58 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS,
BY REGION, 2019–2026 (USD MILLION) 112
6.3.5 DILUENTS 113
6.3.5.1 Diluents are used to prepare antibody solutions 113
TABLE 59 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION,
2019–2026 (USD MILLION) 113
TABLE 60 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 113
TABLE 61 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION) 114
TABLE 62 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION) 114
TABLE 63 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2019–2026 (USD MILLION) 114
6.3.6 ORGANIC SOLVENTS 115
6.3.6.1 Organic solvents prevent physical damage in specimens and improve clarity while visualizing tissue samples 115
TABLE 64 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2019–2026 (USD MILLION) 115
TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 67 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 68 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS,
BY REGION, 2019–2026 (USD MILLION) 116
6.3.7 PROTEOLYTIC ENZYMES 117
6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies 117
TABLE 69 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,
BY REGION, 2019–2026 (USD MILLION) 117
TABLE 70 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 71 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 72 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,
BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 73 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,
BY REGION, 2019–2026 (USD MILLION) 118
6.3.8 OTHER REAGENTS 119
6.3.8.1 Other reagents include antigen retrieval solutions, stabilizers, controls, and mounting solutions 119
TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2019–2026 (USD MILLION) 119
TABLE 75 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 76 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 77 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS,
BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 78 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS,
BY REGION, 2019–2026 (USD MILLION) 121
6.4 EQUIPMENT 121
TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION,
2019–2026 (USD MILLION) 121
TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 82 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 83 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2019–2026 (USD MILLION) 122
TABLE 84 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 123
6.4.1 SLIDE-STAINING SYSTEMS 123
6.4.1.1 Development of high throughput staining systems to drive market growth 123
TABLE 85 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS,
BY REGION, 2019–2026 (USD MILLION) 123
TABLE 86 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 87 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 88 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 89 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 125
6.4.2 TISSUE PROCESSING SYSTEMS 125
6.4.2.1 Technological advancements and need for automation due to shortage of skilled workforce to drive market growth 125
TABLE 90 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS,
BY REGION, 2019–2026 (USD MILLION) 125
TABLE 91 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 92 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 93 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 94 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 127
6.4.3 SLIDE SCANNERS 127
6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth 127
TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2019–2026 (USD MILLION) 128
TABLE 96 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION) 128
TABLE 97 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY COUNTRY, 2019–2026 (USD MILLION) 128
TABLE 98 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY COUNTRY, 2019–2026 (USD MILLION) 129
TABLE 99 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY REGION, 2019–2026 (USD MILLION) 129
6.4.4 OTHER EQUIPMENT 129
TABLE 100 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2019–2026 (USD MILLION) 130
TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 103 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY COUNTRY, 2019–2026 (USD MILLION) 131
TABLE 104 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY REGION, 2019–2026 (USD MILLION) 131
6.5 KITS 131
TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION,
2019–2026 (USD MILLION) 132
TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS,
BY COUNTRY, 2019–2026 (USD MILLION) 132
TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,
2019–2026 (USD MILLION) 132
TABLE 108 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,
2019–2026 (USD MILLION) 133
TABLE 109 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION,
2019–2026 (USD MILLION) 133
TABLE 110 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,
2019–2026 (USD MILLION) 133
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 134
6.5.1.1 Increasing focus on cancer research to fuel market growth 134
TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION) 134
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 135
6.5.2.1 Increasing preclinical drug testing to drive market growth 135
TABLE 112 IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION) 135
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 136
7.1 INTRODUCTION 137
TABLE 113 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
7.2 DIAGNOSTIC APPLICATIONS 137
TABLE 114 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 138
TABLE 115 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 116 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 117 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 139
TABLE 118 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 139
TABLE 119 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2019–2026 (USD MILLION) 139
7.2.1 CANCER 140
7.2.1.1 Growing use of IHC tests for cancer diagnostics to fuel market growth 140
TABLE 120 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 140
TABLE 121 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION,
2019–2026 (USD MILLION) 142
TABLE 122 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER,
BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 123 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION) 142
TABLE 124 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION) 143
TABLE 125 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION,
2019–2026 (USD MILLION) 143
7.2.2 INFECTIOUS DISEASES 143
7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market growth 143
TABLE 126 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 144
TABLE 127 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION) 145
TABLE 128 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 145
TABLE 129 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 145
TABLE 130 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 146
TABLE 131 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2019–2026 (USD MILLION) 146
7.2.3 NEPHROLOGICAL DISEASES 146
7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth 146
TABLE 132 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES,
BY REGION, 2019–2026 (USD MILLION) 147
TABLE 133 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 147
TABLE 134 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 147
TABLE 135 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 148
TABLE 136 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION) 148
7.2.4 AUTOIMMUNE DISEASES 148
7.2.4.1 Availability of numerous primary antibodies and rapid processing of results makes IHC a favorable diagnostic approach 148
TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2019–2026 (USD MILLION) 149
TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 149
TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 149
TABLE 140 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 150
TABLE 141 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2019–2026 (USD MILLION) 150
7.2.5 NEUROLOGICAL DISEASES 150
7.2.5.1 Increasing global burden of neurological diseases to propel market growth 150
TABLE 142 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM 151
TABLE 143 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES,
BY REGION, 2019–2026 (USD MILLION) 151
TABLE 144 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 151
TABLE 145 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 152
TABLE 146 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 152
TABLE 147 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION) 152
7.2.6 OTHER DISEASES 153
TABLE 148 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2019–2026 (USD MILLION) 153
TABLE 149 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 153
TABLE 150 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 154
TABLE 151 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 154
TABLE 152 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY REGION, 2019–2026 (USD MILLION) 154
7.3 RESEARCH APPLICATIONS 155
TABLE 153 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 155
TABLE 154 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 155
TABLE 155 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 156 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 157 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 156
TABLE 158 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 157
7.3.1 DRUG DEVELOPMENT & TESTING 157
7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing 157
TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2019–2026 (USD MILLION) 158
7.3.2 OTHER RESEARCH APPLICATIONS 158
TABLE 160 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 158
7.4 FORENSIC APPLICATIONS 159
TABLE 161 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 159
TABLE 162 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 159
TABLE 163 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 160
TABLE 164 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 160
TABLE 165 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 160
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER 161
8.1 INTRODUCTION 162
TABLE 166 IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 162
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 162
8.2.1 INCREASING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES 162
TABLE 167 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 163
TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 163
TABLE 169 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 163
TABLE 170 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 164
TABLE 171 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 164
8.3 ACADEMIC & RESEARCH INSTITUTES 164
8.3.1 INCREASING USE OF IHC TESTS FOR DRUG DEVELOPMENT AND DISEASES DIAGNOSIS TO SUPPORT MARKET GROWTH 164
TABLE 172 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 165
TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 165
TABLE 174 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 165
TABLE 175 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 166
TABLE 176 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION) 166
8.4 OTHER END USERS 166
TABLE 177 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION) 167
TABLE 178 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER
END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 167
TABLE 179 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION) 167
TABLE 180 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION) 168
TABLE 181 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY REGION, 2019–2026 (USD MILLION) 168
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 169
9.1 INTRODUCTION 170
FIGURE 30 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 170
TABLE 182 IMMUNOHISTOCHEMISTRY MARKET, BY REGION,
2019–2026 (USD MILLION) 170
9.2 NORTH AMERICA 171
FIGURE 31 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 171
TABLE 183 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 172
TABLE 184 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 172
TABLE 185 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 186 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 188 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 173
TABLE 189 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 174
TABLE 190 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 174
9.2.1 US 174
9.2.1.1 US is largest country-level market for immunohistochemistry 174
TABLE 191 RECENT DEVELOPMENTS IN US IHC MARKET 175
TABLE 192 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 176
TABLE 193 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 194 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 195 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 177
TABLE 196 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 177
TABLE 197 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2019–2026 (USD MILLION) 177
TABLE 198 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 178
9.2.2 CANADA 178
9.2.2.1 Increasing cancer cases in Canada to propel market growth 178
TABLE 199 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 178
TABLE 200 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 201 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 202 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 203 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 180
TABLE 204 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 180
TABLE 205 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 180
9.3 EUROPE 181
TABLE 206 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET 181
TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 182
TABLE 208 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 182
TABLE 209 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 210 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 211 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 212 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 183
TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 184
TABLE 214 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 184
9.3.1 GERMANY 184
9.3.1.1 Germany to dominate European IHC market 184
TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 185
TABLE 216 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 217 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 218 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 219 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 186
TABLE 220 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 186
TABLE 221 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 187
9.3.2 FRANCE 187
9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market growth 187
TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 188
TABLE 223 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 188
TABLE 224 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION) 188
TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 226 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 189
TABLE 227 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 189
TABLE 228 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 190
9.3.3 UK 190
9.3.3.1 Increasing number of cancer research studies to support market growth 190
TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 191
TABLE 230 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 231 UK: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 192
TABLE 233 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 192
TABLE 234 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2019–2026 (USD MILLION) 192
TABLE 235 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 193
9.3.4 ITALY 193
9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy 193
TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 193
TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 194
TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 194
TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 194
TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 195
TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 195
TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 195
9.3.5 SPAIN 196
9.3.5.1 Increasing demand for personalized medicine will drive demand for IHC tests to find potential biomarkers 196
TABLE 243 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 196
TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 196
TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 197
TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 197
TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 197
TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 198
TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 198

9.3.6 REST OF EUROPE 198
TABLE 250 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 199
TABLE 251 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 199
TABLE 252 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 200
TABLE 253 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 200
TABLE 254 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 200
TABLE 255 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 201
TABLE 256 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 201
9.4 ASIA PACIFIC 202
FIGURE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 202
TABLE 257 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET 203
TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 203
TABLE 259 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 204
TABLE 260 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 261 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 262 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY TYPE, 2019–2026 (USD MILLION) 205
TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 205
TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 205
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 206
9.4.1 JAPAN 206
9.4.1.1 Japan to dominate Asia Pacific immunohistochemistry market 206
TABLE 266 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 206
TABLE 267 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 268 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 207
TABLE 269 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 270 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 208
TABLE 271 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 208
TABLE 272 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 208
9.4.2 CHINA 209
9.4.2.1 China to register highest growth during forecast period 209
TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 209
TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 210
TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 210
TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 210
TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 211
TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 211
9.4.3 INDIA 211
9.4.3.1 India is key destination for high-end pathology and diagnostic services 211
TABLE 280 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 212
TABLE 281 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 212
TABLE 282 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 213
TABLE 283 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 213
TABLE 284 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 213
TABLE 285 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 214
TABLE 286 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 214
9.4.4 REST OF ASIA PACIFIC 214
TABLE 287 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 215
TABLE 288 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 215
TABLE 289 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION) 216
TABLE 290 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 216
TABLE 291 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 216
TABLE 292 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 217
TABLE 293 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 217
9.5 REST OF THE WORLD 218
TABLE 294 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY REGION,
2019–2026 (USD MILLION) 218
TABLE 295 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 218
TABLE 296 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 218
TABLE 297 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 219
TABLE 298 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 219
TABLE 299 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 219
TABLE 300 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 220
TABLE 301 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 220
9.5.1 LATIN AMERICA 220
9.5.1.1 Increasing incidence of cancer in Latin America driving market growth 220
TABLE 302 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 221
TABLE 303 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION) 221
TABLE 304 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 221
TABLE 305 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION) 222
TABLE 306 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 222
TABLE 307 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 222
TABLE 308 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 223
9.5.2 MIDDLE EAST AND AFRICA 223
9.5.2.1 Government initiatives focused on boosting healthcare infrastructure development to drive market growth 223
TABLE 309 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 223
TABLE 310 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION) 224
TABLE 311 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2019–2026 (USD MILLION) 224
TABLE 312 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2019–2026 (USD MILLION) 224
TABLE 313 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 225
TABLE 314 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION) 225
TABLE 315 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2019–2026 (USD MILLION) 225
10 COMPETITIVE LANDSCAPE 226
10.1 OVERVIEW 226
10.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 227
FIGURE 33 KEY PLAYERS STRATEGIES IN IMMUNOHISTOCHEMISTRY MARKET,
2019- 2021 227
10.3 MARKET SHARE ANALYSIS 228
FIGURE 34 IMMUNOHISTOCHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 228
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 229
FIGURE 35 TOP MARKET PLAYERS DOMINATED IMMUNOHISTOCHEMISTRY MARKET FOR PAST 5 YEARS 229
10.5 COMPANY EVALUATION QUADRANT 230
10.5.1 STARS 230
10.5.2 EMERGING LEADERS 230
10.5.3 PERVASIVE 230
10.5.4 EMERGING COMPANIES 230
FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2020 231
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 232
10.6.1 PROGRESSIVE COMPANIES 232
10.6.2 STARTING BLOCKS 232
10.6.3 RESPONSIVE COMPANIES 232
10.6.4 DYNAMIC COMPANIES 232
FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 233
10.7 COMPANY PRODUCT FOOTPRINT 234
TABLE 316 PRODUCT PORTFOLIO ANALYSIS: IMMUNOHISTOCHEMISTRY MARKET (2020) 234
10.8 COMPANY GEOGRAPHIC FOOTPRINT 235
TABLE 317 GEOGRAPHIC REVENUE MIX: IMMUNOHISTOCHEMISTRY MARKET (2020) 235
10.9 COMPETITIVE SCENARIO 236
10.9.1 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–MARCH 2021 236
10.9.2 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2019–MARCH 2021 237
10.9.3 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS,
JANUARY 2019–MARCH 2021 239

11 COMPANY PROFILES 240
11.1 KEY COMPANIES 240
(Business overview, Products and Services offered, Recent developments, MNM view)*
11.1.1 F. HOFFMANN-LA ROCHE AG 240
TABLE 318 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 240
FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 241
11.1.2 DANAHER CORPORATION 248
TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW 248
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 249
11.1.3 AGILENT TECHNOLOGIES, INC. 255
TABLE 320 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 255
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 256
11.1.4 MERCK KGAA 263
TABLE 321 MERCK KGAA: BUSINESS OVERVIEW 263
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2020) 264
11.1.5 BIO-RAD LABORATORIES, INC. 273
TABLE 322 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 273
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 274
11.1.6 BIO-TECHNE CORPORATION 279
TABLE 323 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 279
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020) 280
11.1.7 ABCAM PLC 283
TABLE 324 ABCAM PLC: BUSINESS OVERVIEW 283
FIGURE 44 ABCAM PLC: COMPANY SNAPSHOT (2020) 284
11.1.8 BECTON, DICKINSON AND COMPANY 290
TABLE 325 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 290
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 291
11.1.9 PERKINELMER, INC. 296
TABLE 326 PERKINELMER, INC.: BUSINESS OVERVIEW 296
FIGURE 46 PERKINELMER, INC.: COMPANY SNAPSHOT (2020) 297
11.1.10 TAKARA BIO, INC. 300
TABLE 327 TAKARA BIO, INC.: BUSINESS OVERVIEW 300
FIGURE 47 TAKARA BIO, INC.: COMPANY SNAPSHOT (2020) 300
11.1.11 THERMO FISHER SCIENTIFIC, INC. 302
TABLE 328 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 302
FIGURE 48 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 303
11.1.12 PHC HOLDINGS CORPORATION 307
TABLE 329 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 307
11.1.13 CELL SIGNALING TECHNOLOGY, INC. 313
TABLE 330 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 313
11.1.14 BIO SB, INC. 317
TABLE 331 BIO SB, INC.: BUSINESS OVERVIEW 317
11.1.15 MILTENYI BIOTEC 322
TABLE 332 MILTENYI BIOTEC: BUSINESS OVERVIEW 322
11.1.16 CANDOR BIOSCIENCE GMBH 326
TABLE 333 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW 326
11.1.17 SAKURA FINETEK JAPAN CO., LTD. 327
TABLE 334 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 327
11.2 OTHER PLAYERS 332
11.2.1 EAGLE BIOSCIENCES, INC. 332
TABLE 335 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW 332
11.2.2 BIOCARE MEDICAL, LLC 333
TABLE 336 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 333
11.2.3 ELABSCIENCE, INC. 335
TABLE 337 ELABSCIENCE, INC.: COMPANY OVERVIEW 335
11.2.4 BIO-GENEX LABORATORIES 336
TABLE 338 BIO-GENEX LABORATORIES: COMPANY OVERVIEW 336
11.2.5 DIAGNOSTIC BIOSYSTEMS, INC. 339
TABLE 339 DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW 339
11.2.6 BIOVISION, INC. 342
TABLE 340 BIOVISION, INC.: COMPANY OVERVIEW 342
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 343
TABLE 341 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW 343
11.2.8 GENEMED BIOTECHNOLOGIES, INC. 344
TABLE 342 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 344
*Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 346
12.1 DISCUSSION GUIDE 346
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 349
12.3 AVAILABLE CUSTOMIZATIONS 351
12.4 RELATED REPORTS 351
12.5 AUTHOR DETAILS 352


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com